Medicaid cuts push GLP-1 weight-loss drugs out of reach for low-income patients
TL;DR Summary
Massachusetts and several other states have halted or reduced Medicaid coverage for GLP-1 weight-loss medications, leaving low-income patients who started treatment unable to continue. Coverage had been about a third of states in mid-2025, but by 2026 the share fell to roughly one in five, underscoring widening disparities in access to obesity therapies due to high costs.
- Some people are getting shut out when it comes to GLP-1 drugs. Here’s why. The Washington Post
- CEO of major Mass. health insurer discusses choice to restrict GLP-1 weight-loss drugs The Boston Globe
- The GLP-1 paradox: too expensive to cover, too effective to cut Fortune
- The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients ScienceDaily
- Controversy surrounding diabetes drug, Ozempic, being used for weight loss LiveNOW from FOX
Reading Insights
Total Reads
1
Unique Readers
8
Time Saved
20 min
vs 21 min read
Condensed
99%
4,144 → 57 words
Want the full story? Read the original article
Read on The Washington Post